tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
OKYO Pharma Limited Sponsored ADR (OKYO)
NASDAQ:OKYO
US Market
OKYO
OKYO Pharma Limited Sponsored ADR
Overview
AI Stock Analysis
Popular
Dividends
Earnings
Ownership
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Advertisement

OKYO Pharma Limited Sponsored ADR (OKYO) Stock News & Sentiment

Compare
81 Followers
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development
Premium
Company Announcements
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development
8h ago
6K
OKYO
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation
Premium
Ratings
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation
1d ago
OKYO
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain
Premium
Company Announcements
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain
1d ago
6K
OKYO
OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention
Premium
Company Announcements
OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention
1M ago
6K
OKYO
OKYO Pharma CEO to Present at Boston Drug Discovery Summit
Premium
Company Announcements
OKYO Pharma CEO to Present at Boston Drug Discovery Summit
2M ago
6K
OKYO
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain
Premium
Company Announcements
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain
3M ago
6K
OKYO
Promising Developments in OKYO Pharma’s Urcosimod Program Drive Buy Rating and $7 Price Target
Premium
Ratings
Promising Developments in OKYO Pharma’s Urcosimod Program Drive Buy Rating and $7 Price Target
3M ago
OKYO
More OKYO News >

OKYO News on the Web

OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain
TipRanks News
Neutral
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain
Proactive Investors
Neutral
OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts
Proactive Investors
Bullish
OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention
TipRanks News
Neutral
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit
Proactive Investors
Neutral
OKYO moves toward FDA talks after eye drug trial – ICYMI
Proactive Investors
Neutral
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain
Proactive Investors
Neutral
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain
Proactive Investors
Neutral

News Score - Last 7 Days

Neutral
OKYO
Sector Average
Media Buzz
This Week2 articles
Weekly Average1 articles
News Sentiment
This Week59%
Sector Average56%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is OKYO’s Media Buzz Sentiment?
2 articles about OKYO were published this week. In an average week, 1 articles are published.
    What is OKYO’s weekly average amount of articles?
    In an average week, 1 articles about OKYO are published.
      What is OKYO’s News Sentiment?
      59% of articles about OKYO were positive this week, compared to its sector average of 56%.
        Healthcare Stocks that are Trending in the News
        NEVIPascal Biosciences Inc
        JNJJohnson & Johnson
        HRMYHarmony Biosciences Holdings
        WATWaters
        ABTAbbott Laboratories
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing